Methyl 5-cyclopropylisoxazole-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Methyl 5-cyclopropylisoxazole-3-carboxylate
• 英文别名: methyl 5-cyclopropyl-1,2-oxazole-3-carboxylate
• 化学式: C₈H₉NO₃
• mdl: MFCD07390343
• 分子量: 167.16
• InChiKey: GLVAWJNBOCMLMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINECOMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLYL[4,3-C]PYRIDINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2019143994A1

  公开（公告）日：2019-07-25

  Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  提供以下式I的化合物：及其互变异构体和药用可接受的盐和溶剂化物，其中R1、R2和R3具有说明书中给出的含义，它们是RET激酶的抑制剂，可用于治疗和预防可通过RET激酶抑制剂治疗的疾病，包括RET相关疾病和失调。
• Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma Inc.

  公开号：US11472802B2

  公开（公告）日：2022-10-18

  Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2 and R3 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了式 I：及其同系物和药学上可接受的盐和溶液的化合物，其中 R1、R2 和 R3 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可使用 RET 激酶抑制剂治疗的疾病，包括 RET 相关疾病和紊乱。
• COMPOUNS, COMPOSITIONS AND METHODS OF USE
  申请人：Aquinnah Pharmaceuticals Inc.

  公开号：EP3557998A1

  公开（公告）日：2019-10-30
• SUBSTITUTED PYRAZOLYL[4,3-C]PYRIDINECOMPOUNDS AS RET KINASE INHIBITORS
  申请人：Array Biopharma, Inc.

  公开号：EP3740486A1

  公开（公告）日：2020-11-25
• COMPOUNDS, COMPOSITIONS AND METHODS OF USE
  申请人：Aquinnah Pharmaceuticals, Inc.

  公开号：US20200270211A1

  公开（公告）日：2020-08-27

  Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.